Sat, Aug 2, 2014, 6:19 AM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

SIGA Technologies, Inc. Message Board

nicehedges 12 posts  |  Last Activity: Jul 29, 2014 7:09 AM Member since: Feb 15, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • nicehedges nicehedges Jul 29, 2014 7:09 AM Flag

    Yes Eiseman and Hudson are still at it.
    Here is the Summary from Hudson::::::::::
    -------Delaware SC has sent Judge Parsons clear instructions to consider a lump sum expectation damage or reliance damage award.
    -------Judge Parsons' own words about an equitable payment stream option: "Admittedly, there is little precedent to aid this Court in fashioning an appropriate remedy for the breach SIGA committed.".
    -------I have changed my mind. Now I believe that an unjust enrichment award is possible but it won't be an amount that is significantly more than a reliance damage award.
    And his Conclusion::::::::::
    I actually appreciate anyone, especially Dr. Eiseman, who will provide me documented information which refutes any of the statements or information provided in this article. The last thing I want to do is to hold on to an investment based on false assumptions.
    I am long both SIGA and PharmAthene as I believe both stocks are undervalued. I believe anyone who invests in both of these companies will come out significantly ahead when (or should I say if) Judge Parsons delivers his opinion as long as it is not one that keeps these two companies embroiled in this lawsuit. However, since I believe that SIGA will come out on top, I would recommend using most of your money to invest in SIGA stock.

  • Reply to


    by sigakingone Jul 27, 2014 9:55 AM
    nicehedges nicehedges Jul 27, 2014 10:31 AM Flag

    Nice find KING! This is relatively a recent study.
    First received: March 4, 2014
    Last updated: NA
    Last verified: March 2014
    History: No changes posted
    Inclusion Criteria:
    DoD-affiliated personnel (including US civilian employees, contractors and other US personnel and dependents, as well as allied military forces and local nationals) of any age, not breastfeeding
    Has been exposed to or infected with orthopox viruses (ie, variola (smallpox), vaccinia, monkeypox, or cowpox) OR Has developed serious complications from vaccinia vaccination (eg, eczema vaccinatum, progressive vaccinia, generalized vaccinia that is severe or persistent, and select cases of inadvertent inoculation due to severe pain related to mucosal involvement, ocular involvement) resulting from vaccination, secondary transmission, or other exposure
    Is available for clinical follow-up for duration of the treatment and follow-up period
    Must be able to swallow capsules
    Exclusion Criteria:
    Has hypersensitivity to tecovirimat
    Unable or unwilling to cooperate with the requirements of the treatment protocol
    Breast-feeding patients. Note that breast-feeding females will be counseled that tecovirimat has not been studied in breast-feeding women and may opt to cease breast-feeding for the duration of the treatment and at least 30 days after the last dose of drug and thus be eligible for enrollment. Women who choose to continue breast-feeding will not be enrolled in this treatment protocol.

  • Reply to

    BBC: Dengue Vaccine Progress

    by nicehedges Jul 12, 2014 8:26 PM
    nicehedges nicehedges Jul 17, 2014 6:31 AM Flag

    I have family from Puerto Rico where Dengue is also endemic. They basically fear for the young, old and other immuno compromised individuals that get sick. If you are not in these groups the perception is you will muscle through the sickness unless you pick up the hemorrhagic form where your odds get a bit dicey. I live in Miami now where last week the local media has been pounding a story of the this season's first locally acquired case. They say the woman made a full recovery. Some sort of update out of Siga would be nice on their dengue candidate, or any other program for that matter.

  • Scientists say they have developed the world's first vaccine against dengue fever seen to work in large-scale trials.
    10 July 2014

    Research in the Lancet journal suggests more than 50% of children who are given the vaccine are protected against the disease.

    Half the world's population are at risk of catching the mosquito-borne virus.

    Experts say though the long-awaited study is promising, vaccines with greater effectiveness are crucial.

    There are currently no treatments to prevent dengue fever - an illness which affects more than one million people a year.

    'Best so far'
    In the largest late-stage trial of a vaccine to date, researchers from five centres across Asia treated 6,000 children aged between two and 14 years old.

    Some 56% were seen to have protection against the virus at the end of two years.

    It worked best for children with certain subtypes of the virus and those who had been exposed to it before.

    And the vaccine had an even greater impact on severe forms of the disease, reducing the number of people needing treatment in hospital and preventing 80% of cases of haemorrhagic fever - a potentially life-threatening complication.

    Lead author Dr Maria Rosario Capeding, from the Research Institute for Tropical Medicine in the Philippines, told the BBC: "Given that dengue is a major public health problem in most Asian countries the findings have the potential to have a huge impact on public health.

    "A 56% reduction, though moderate, can translate into a huge benefit for countries plagued by the disease."

  • Reply to

    Deaths from Monkeypox in the Congo

    by nicehedges Jun 22, 2014 11:14 AM
    nicehedges nicehedges Jun 25, 2014 6:50 AM Flag

    "bush meat"!

  • Reply to

    Deaths from Monkeypox in the Congo

    by nicehedges Jun 22, 2014 11:14 AM
    nicehedges nicehedges Jun 23, 2014 6:59 AM Flag

    If it were to develop into anything significant I would say the WHO would intervene, and yes they have $$$ and knowledge of 246.

  • Published On: Sun, Jun 22nd, 2014

    "Two people died from a disease that has the same symptoms as monkeypox; 12 cases recorded in two weeks, in the locality of Bangangala in territory Bomongo (Equatuer), Democratic Republic of the Congo(DRC), according to a Radio Okapi report (computer translated). Health specialists have not yet confirmed if it is really the disease monkeypox.

    “I have already called the Minister of Public Health. I even wrote him and I booked a copy to the Prime Minister and I expect the government to act quickly.Health centers do not have the required infrastructure to accommodate the sick and administer appropriate care , “said Patrick Mayombe.

    It is a relatively rare virus found primarily in central and western Africa. The disease is caused by Monkeypox virus. It is closely related to the smallpox virus (variola), the virus used in the smallpox vaccine (vaccinia), and the cowpox virus...."

  • Reply to

    Only One patient so far on HDF

    by telecominvest May 15, 2014 8:57 PM
    nicehedges nicehedges May 15, 2014 10:26 PM Flag

    wow, impressive digging telecominvest! Thanks for sharing

  • Reply to

    Wow, its actually happening (well kind of)

    by metuchen1969 May 13, 2014 3:32 PM
    nicehedges nicehedges May 13, 2014 8:57 PM Flag

    I could not agree more. This is awesome news. As we all know, Davita is HUGE, and if they like what they see during the trial Neph could be bought out in an instant. Start Dreaming is RIGHT!!!!

  • nicehedges by nicehedges May 13, 2014 8:53 PM Flag

    Check out the PR from Nephros today ( NEPH ). Davita is doing a 6 month trial of Neph's hemodiafiltration technology in one of their colorado clinics. Nephros has been deploying this technology in Europe for years now and has a favorable track record. If Davita likes what they see during the trial, I would not be surprised to see them scoup up little Neph.

  • nicehedges nicehedges May 3, 2014 7:36 AM Flag

    Here is another article from guardianlvDOTcom:
    Three people have now been infected with a cousin of the infamous smallpox virus in the country of Georgia, which marks the crossroads between Western Asia and Eastern Europe. American scientists from the Center of Disease Control (CDC) detected this new virus in three people, including two herdsmen who somehow had been infected by their livestock. The virus currently has no name and belongs to a family of viruses called orthopoxvirus that includes cowpox and smallpox.

    Neil Vora, who led the CDC team, said in an NPR report that it is not known if this new virus could be transmitted from human to human, but it could be transmitted from animals to humans. “But how many people are getting sick? Are animals getting sick? We don’t know. We don’t know if it has caused any deaths,” Vora said.

    The two herdsmen, who were not vaccinated against smallpox, got sick last summer after making contact with sick cattle. The CDC team investigated and conducted tests, confirming that the men were infected with an unknown type of orthopoxvirus. Like smallpox, this new virus causes painful blisters on the arms and hands, swollen lymph nodes, high fever and physical weakness. The CDC team also interviewed 55 people who were in contact with the sick cattle or herdsmen. They found five of the nine interviewees had orthopoxvirus antibodies in their bloodstream and found a third person who contracted the disease in 2010, but was thought to have anthrax, according to the CDC report.

    People who are vaccinated with one type of orthopoxvirus will also be protected against other viruses in the family, according to Vora. The viruses include cowpox, monkeypox, smallpox and vaccinia. Since smallpox vaccinations stopped in Georgia in 1980, this cousin of the smallpox virus began to proliferate among rodents, which could infect livestock and people. Although the herdsmen have recovered, the relatives of the smallpox virus could be deadly to .....

  • nicehedges nicehedges May 3, 2014 7:30 AM Flag

    Nice post TLA. My alerts are getting hit with the same story. Here's one from livescienceDOTcom:

    By Marc Lallanilla, Assistant Editor | May 02, 2014 02:21pm ET
    Smallpox, the disfiguring scourge that killed an estimated 300 million to 500 million people in the 20th century alone, has been eradicated worldwide, thanks to an aggressive vaccination campaign.

    But smallpox has relatives that are also deadly: The virus that causes smallpox is an orthopoxvirus, a family of viral agents that also cause cowpox, monkeypox, vaccinia and other diseases.

    And now, the Centers for Disease Control and Prevention (CDC) has announced that a new orthopoxvirus has been discovered in two men from the nation of Georgia in western Asia. Though both men survived the disease, disease experts aren't taking any chances. [5 Most Likely Real-Life Contagions]

    A bioterrorism threat?
    Dr. Neil Vora, a "disease detective" with the CDC's Epidemic Intelligence Service (EIS), flew to Georgia to investigate the unusual case. The men — both herdsmen who had daily contact with cows and other livestock — had painful blisters on their bodies, a fever and swollen lymph nodes.

    "We consider this family of viruses very important because smallpox could be used as a bioterrorism agent," Vora told NPR.

    The bioterrorism potential of poxviruses is real enough that the U.S. government last year began to build a smallpox medicine stockpile large enough to treat 2 million people, according to The New York Times.

    "With today’s patterns of global travel and trade, disease can spread nearly anywhere within 24 hours," EIS chief Dr. Diana Bensyl said in a CDC statement. "There's still a lot left to do to improve health security and respond more quickly to outbreaks."

    Making the leap from animals to humans
    Vora and other infectious disease experts believe the new poxvirus spread to the two men from cattle. Most of the orthopoxviruses typically infect animals, then jump to humans who have close contact with ani...

2.55-0.09(-3.41%)Aug 1 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Icahn Enterprises, L.P.
NasdaqGSFri, Aug 1, 2014 3:59 PM EDT
Marriott International, Inc.
NasdaqGSFri, Aug 1, 2014 4:00 PM EDT